Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced ovarian cancer, and altered the natural histo...
Main Authors: | Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/9/3/87 |
Similar Items
-
PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
by: Stergios Boussios, et al.
Published: (2019-05-01) -
Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
by: Katarzyna Kluzek, et al.
Published: (2012-06-01) -
Wise Management of Ovarian Cancer: On the Cutting Edge
by: Stergios Boussios, et al.
Published: (2020-05-01) -
Molecular determinants of sensitivity to poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer
by: O'Connor, Kevin William
Published: (2016) -
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
by: Ohmoto A, et al.
Published: (2017-10-01)